RT Journal Article
SR Electronic
T1 Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.07.20093831
DO 10.1101/2020.05.07.20093831
A1 Yang, Tzu-Han
A1 Chou, Chian-Ying
A1 Yang, Yi-Fan
A1 Yang, Yi-Ping
A1 Chien, Chian-Shiu
A1 Yarmishyn, Aliaksandr A.
A1 Yang, Tzu-Ying
A1 Chiou, Shih-Hwa
A1 Chang, Yuh-Lih
YR 2020
UL http://medrxiv.org/content/early/2020/05/14/2020.05.07.20093831.abstract
AB Backgrounds Since COVID-19 outbreak, various agents have been tested but no proven effective therapies have been identified. This has led to a lot of controversies among associated researches. Hence, in order to address the issue of using hydroxychloroquine (HCQ) in treating COVID-19 patients, we conducted a systematic review and meta-analysis.Methods A thorough search was carried out to find relevant studies in MEDLINE, medRxiv, PubMed, Cochrane Database, China Academic Journals Full-text Database and Web of Science. Two investigators independently reviewed 274 abstracts and 23 articles. The trials which evaluated HCQ for treatment of COVID-19 were included for this systematic review. Two investigators assessed quality of the studies and data extraction was done by one reviewer and cross checked by the other.Results Five trials involving 677 patients were included while conducting the meta-analysis. Compared with the control group, HCQ with or without azithromycin (AZI) showed benefits in viral clearance of SARS-CoV-2 (odds ratio (OR) 1.95, 95% CI 0.19-19.73) and a reduction in progression rate (OR 0.89, 95% CI 0.58-1.37), but without demonstrating any statistical significance. This systematic review has also suggested a possible synergistic effect of the combination therapy which included HCQ and AZI. However, the use of HCQ was associated with increased mortality in COVID-19 patients.Conclusions The use of HCQ with or without AZI for treatment of COVID-19 patients, seems to be effective. The combination of HCQ and AZI has shown synergistic effects. However, mortality rate was increased when the treatment was conducted with HCQ.Summary of the article’s main point This study demonstrates that the use of hydroxychloroquine with or without azithromycin might have benefits in viral clearance of SARS-CoV-2 and reduction of progression rate, but was associated with increased mortality in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported partly by Taipei Veterans General Hospital (V109EA-014, VGH-2017/2020 C and E project).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.